Beranda › Leukemia › Massachusetts › Boston
Uji klinis Leukemia di Boston, MA
25 studi untuk Leukemia mencari peserta di lokasi sekitar Boston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Menerima pesertaFase 2
- Dana-Farber Cancer Institute, Boston
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Menerima peserta
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Menerima pesertaFase 3
- Research Site, Boston
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Menerima pesertaFase 2
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
Menerima pesertaFase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Menerima pesertaFase 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Menerima pesertaFase 1
- Beth Israel Deaconess Medical Center, Boston
ALL Backbone in AYAs
Menerima pesertaFase 2
- Dana Farber Cancer Institute, Boston
Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
Menerima peserta
- Mass General Brigham Cancer Institute, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Menerima pesertaSukarelawan sehat diterima
- Dana-Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Menerima pesertaFase 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Menerima pesertaFase 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Menerima pesertaFase 1/2
- Dren Investigational Site, Boston
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Menerima pesertaFase 1
- Dana-Farber Cancer Institute, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Menerima pesertaStudi observasional
- Dana-Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Menerima pesertaFase 2/3
- Dana-Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Menerima peserta
- Massachusetts General Hospital Cancer Center, Boston
Shwachman Diamond Syndrome Registry and Study
Menerima pesertaStudi observasional
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
Menerima pesertaFase 1
- Dana-Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Menerima pesertaFase 1
- Massachusetts General Hospital, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Menerima pesertaFase 1/2
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Menerima pesertaFase 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
Menerima pesertaFase 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Menerima peserta
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
Menerima peserta
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Uji klinis Leukemia di kota lain
- Houston, TX28 studi
- New York City, NY19 studi
- Los Angeles, CA16 studi
- Chicago, IL16 studi
- Durham, NC13 studi
- Baldwin Park, CA12 studi
- Columbus, OH12 studi
- Nashville, TN12 studi
- Philadelphia, PA12 studi
- Milwaukee, WI11 studi
- Atlanta, GA11 studi
- Seattle, WA11 studi
Studi lain di Boston
- Kanker Payudara111 studi
- Kanker Paru Non-Sel Kecil90 studi
- Kanker (semua jenis)86 studi
- Kanker Kolorektal63 studi
- Kanker Metastatik63 studi
- Kanker Paru62 studi
- Kanker Ovarium61 studi
- Kanker Prostat59 studi
- Depresi52 studi
- Kanker Endometrium50 studi
- Gagal Jantung44 studi
- Leukemia Mieloid Akut44 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.